Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

被引:328
作者
Dieci, Maria Vittoria [1 ,2 ]
Radosevic-Robin, Nina [3 ,4 ]
Fineberg, Susan [5 ,6 ]
van den Eynden, Gert [7 ,8 ]
Ternes, Nils [9 ,10 ]
Penault-Llorca, Frederique [3 ,4 ,11 ]
Pruneri, Giancarlo [12 ,13 ]
D'Alfonso, Timothy M. [14 ]
Demaria, Sandra [15 ]
Castaneda, Carlos [16 ]
Sanchez, Joselyn [16 ]
Badve, Sunil [17 ]
Michiels, Stefan [9 ,10 ]
Bossuyt, Veerle [18 ]
Rojo, Federico [19 ]
Singh, Baljit [20 ]
Nielsen, Torsten [21 ]
Viale, Giuseppe [22 ]
Kim, Seong-Rim [23 ]
Hewitt, Stephen [24 ]
Wienert, Stephan [25 ]
Loibl, Sybille [26 ]
Rimm, David [18 ]
Symmans, Fraser [27 ]
Denkert, Carsten [28 ]
Adams, Sylvia [29 ]
Loi, Sherene [30 ]
Salgado, Roberto [31 ,32 ,33 ]
机构
[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
[2] IRCCS, Med Oncol 2, Veneto Inst Oncol IOV, Padua, Italy
[3] Jean Perrin Comprehens Canc Ctr, Dept Surg Pathol & Biopathol, Clermont Ferrand, France
[4] Univ Auvergne U1240, INSERM, Clermont Ferrand, France
[5] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA
[6] Albert Einstein Coll Med, Bronx, NY 10467 USA
[7] Univ Libre Bruxelles, Inst Jules Bordet, Mol Immunol Unit, Brussels, Belgium
[8] GZA Ziekenhuizen, Dept Pathol, Antwerp, Belgium
[9] Serv Biostat & Epidemiol, Gustave Roussy, B2 M,RdC,114 Rue Edouard Vaillant, F-94805 Villejuif, France
[10] Univ Paris Sud, Univ Paris Saclay, INSERM, Fac Med UVSQ,CESP, F-94805 Villejuif, France
[11] Univ Auvergne, Sch Med, Clermont Ferrand, France
[12] Fdn IRCCS Ist Nazl Tumori, Div Pathol, Milan, Italy
[13] Univ Milan, Sch Med, Milan, Italy
[14] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY USA
[15] Weill Cornell Med, Dept Radiat Oncol, New York, NY USA
[16] Inst Nacl Enfermedades Neoplas, Dept Res, Lima 15038, Peru
[17] Indiana Univ, Dept Pathol & Lab Med, Indianapolis, IN 46204 USA
[18] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA
[19] UAM, Pathol Dept, Fdn Jimenez Diaz, IIS, Madrid, Spain
[20] Coney Isl Hosp, Dept Pathol, New York, NY USA
[21] Univ British Columbia, Dept Pathol & Lab Med, Genet Pathol Evaluat Ctr, Vancouver, BC, Canada
[22] Univ Milan, Ist Europeo Oncol, Dept Pathol, Milan, Italy
[23] NRG Oncol, Natl Surg Adjuvant Breast & Bowel Project Operat, Pittsburgh, PA USA
[24] NCI, Expt Pathol Lab, Pathol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
[25] Dlw Laborsoftware UG Haftungsbeschrankt, Lubben, Germany
[26] German Breast Grp, Neu Isenburg, Germany
[27] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[28] Charite Univ Med Berlin, Inst Pathol, Berlin, Germany
[29] NYU, Sch Med, Perlmutter Canc Ctr, New York, NY USA
[30] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[31] Peter Mac Callum Canc Ctr, Translat Breast Canc Genom & Therapeut Lab, Melbourne, Vic, Australia
[32] Jules Border Inst, Breast Canc Translat Res Lab, Brussels, Belgium
[33] GZA, Dept Pathol, Antwerp, Belgium
关键词
Tumor-infiltrating lymphocytes; Breast cancer; Neoadjuvant; Residual disease; Ductal carcinoma in situ; Residual cancer burden; PATHOLOGICAL COMPLETE RESPONSE; PREDICTIVE-VALUE; CHEMOTHERAPY; TRASTUZUMAB; SURVIVAL; CARBOPLATIN; BURDEN; DCIS;
D O I
10.1016/j.semcancer.2017.10.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.
引用
收藏
页码:16 / 25
页数:10
相关论文
共 49 条
[1]
Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer [J].
Andre, Fabrice ;
Dieci, Maria V. ;
Dubsky, Peter ;
Sotiriou, Christos ;
Curigliano, Giuseppe ;
Denkert, Carsten ;
Loi, Sherene .
CLINICAL CANCER RESEARCH, 2013, 19 (01) :28-33
[2]
[Anonymous], CANC RES S
[3]
[Anonymous], 2016, BREAST CANC NCCN GUI
[4]
[Anonymous], BREAST CANC RES TREA
[5]
[Anonymous], J CLIN PATHOL
[6]
[Anonymous], CANC RES S
[7]
Asano Y., 2016, CANC RES S, V77
[8]
Beguinot-Comillon M., 2016, CANC RES S14, V76
[9]
The immune system and response to HER2-targeted treatment in breast cancer [J].
Bianchini, Giampaolo ;
Gianni, Luca .
LANCET ONCOLOGY, 2014, 15 (02) :E58-E68
[10]
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].
Cortazar, Patricia ;
Zhang, Lijun ;
Untch, Michael ;
Mehta, Keyur ;
Costantino, Joseph P. ;
Wolmark, Norman ;
Bonnefoi, Herve ;
Cameron, David ;
Gianni, Luca ;
Valagussa, Pinuccia ;
Swain, Sandra M. ;
Prowell, Tatiana ;
Loibl, Sibylle ;
Wickerham, D. Lawrence ;
Bogaerts, Jan ;
Baselga, Jose ;
Perou, Charles ;
Blumenthal, Gideon ;
Blohmer, Jens ;
Mamounas, Eleftherios P. ;
Bergh, Jonas ;
Semiglazov, Vladimir ;
Justice, Robert ;
Eidtmann, Holger ;
Paik, Soonmyung ;
Piccart, Martine ;
Sridhara, Rajeshwari ;
Fasching, Peter A. ;
Slaets, Leen ;
Tang, Shenghui ;
Gerber, Bernd ;
Geyer, Charles E., Jr. ;
Pazdur, Richard ;
Ditsch, Nina ;
Rastogi, Priya ;
Eiermann, Wolfgang ;
von Minckwitz, Gunter .
LANCET, 2014, 384 (9938) :164-172